dual glp 1 and gip receptor agonist The Emerging Role of GLP-1 Agonists in Glycemic Management and Cardiovascular Risk Reduction The mechanisms of dual incretin

Obesity and associated metabolic disorders such as type 2 diabetes mellitus and polycystic ovary syndrome are rising globally, contributing to infertility and adverse pregnancy outcomes

veterans suggests that popular GLP-1 drugs such as semaglutide may do far more than help with diabetes and weight lossthey could also fight addiction itself

This review highlights key clinical considerations across reproductive stages, emphasizes the primacy of human exposure data where available, and identifies critical evidence gaps requiring future prospective study.

evidence from uncontrolled designs (case reports, case series, pharmacovigilance analyses) was initially rated very low certainty, as these designs are inherently uncontrolled and start below the lowest GRADE tier

Although evidence from clinical trials has shown GLP-1 RAs to be safe and efficacious in people living with T2DM and renal impairment, their use is uncommon in this patient population